AI Article Synopsis
- Recent research has identified the free soluble oligosaccharide of GM1 as crucial for neurotrophic functions and explored its therapeutic effects in a Parkinson's disease mouse model.
- Administration of GM1 oligosaccharide significantly alleviated physical symptoms and corrected biochemical abnormalities in the brain, including reducing harmful α-synuclein levels and restoring important neurotransmitter expressions.
- The study suggests that the Parkinson's symptoms in the B4galnt1 mice are linked to low levels of neuronal gangliosides and emphasizes the potential of GM1 oligosaccharide as a treatment for sporadic Parkinson's disease.
Article Abstract
Given the recent in vitro discovery that the free soluble oligosaccharide of GM1 is the bioactive portion of GM1 for neurotrophic functions, we investigated its therapeutic potential in the B4galnt1 mice, a model of sporadic Parkinson's disease. We found that the GM1 oligosaccharide, systemically administered, reaches the brain and completely rescues the physical symptoms, reduces the abnormal nigral α-synuclein content, restores nigral tyrosine hydroxylase expression and striatal neurotransmitter levels, overlapping the wild-type condition. Thus, this study supports the idea that the Parkinson's phenotype expressed by the B4galnt1 mice is due to a reduced level of neuronal ganglioside content and lack of interactions between the oligosaccharide portion of GM1 with specific membrane proteins. It also points to the therapeutic potential of the GM1 oligosaccharide for treatment of sporadic Parkinson's disease.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6920361 | PMC |
| http://dx.doi.org/10.1038/s41598-019-55885-2 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!